Author:
Xie Long,Zhu Xiao-Ya,Xu Li,Xu Xiao-Xie,Ruan Ze-Fan,Huang Ming-Xiang,Chen Li,Jiang Xi-Wen
Abstract
Abstract
Background
Escalating cases of multidrug-resistant tuberculosis (MDR-TB) pose a major challenge to global TB control efforts, necessitating innovative diagnostics to empower decentralized detection of gene mutations associated with resistance to rifampicin (RIF) and isoniazid (INH) in Mycobacterium tuberculosis (M. tuberculosis) in resource-constrained settings.
Methods
Combining multiplex fluorescent PCR and Multiple Probes Melting Analysis, we identified mutations in the rpoB, katG, ahpC and inhA genes from sputum specimens. We first constructed a reference plasmid library comprising 40 prevalent mutations in the target genes’ resistance determining regions and promoters, serving as positive controls. Our assay utilizes a four-tube asymmetric PCR method with specifically designed molecular beacon probes, enabling simultaneous detection of all 40 mutations. We evaluated the assay’s effectiveness using DNA isolated from 50 clinically confirmed M. tuberculosis sputum specimens, comparing our results with those obtained from Sanger sequencing and retrospective validation involving bacteriological culture and phenotypic drug susceptibility testing (pDST). We also included the commercial Xpert MTB/RIF assay for accuracy comparison.
Results
Our data demonstrated remarkable sensitivity in detecting resistance to RIF and INH, achieving values of 93.33% and 95.24%, respectively, with a specificity of 100%. The concordance between our assay and pDST was 98.00%. Furthermore, the accuracy of our assay was comparable to both Sanger sequencing and the Xpert assay. Importantly, our assay boasts a 4.2-h turnaround time and costs only $10 per test, making it an optimal choice for peripheral healthcare settings.
Conclusion
These findings highlight our assay’s potential as a promising tool for rapidly, accurately, and affordably detecting MDR-TB.
Funder
Guangzhou Municipal Bureau of Science and Technology
Guangdong Provincial Department of Science and Technology
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. World Health O. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
2. Eddy JJ, Gadani KM, Tibbs A, Bernardo J, Cochran J, White LF, Horsburgh CR Jr, Jacobson KR. Increasing drug resistance among persons with tuberculosis in Massachusetts, 2009–2018. Open Forum Infect Dis. 2020;7:ofaa300.
3. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med. 1999;160:587–93.
4. World Health O. Global tuberculosis report 2016. Geneva: World Health Organization; 2016.
5. World Health O. Global tuberculosis report 2019. Geneva: World Health Organization; 2019.